Enhertu first secured approval in 2019 for patients with high levels of HER2, a protein that promotes cancer cell growth. In 2022, the drug became the first therapy approved for H

Research that has not yet been peer-reviewed shows the newest blood test is more than 80% accurate in detecting colon cancer in people who had the disease. The test is 90% accurate in ruling out cancer in healthy adults, according to the study published Monday in the Journal of Clinical Oncology.

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety of tumors.

As part of the second Trump Administration's diversity witchhunt, cancer research and other crucial projects have been paused indefinitely. As Mother Jones reports, this administration's pushback against diversity,

Astra is due to pay Daiichi US$175 million in milestones after the US approval, the companies said. Enhertu is cleared in the US and European Union for some breast cancer patients whose cancer spread after receiving treatment, or whose disease returned after surgery.

Zentalis Pharmaceuticals said it would cut 40% of its workforce as part of a restructuring to support the late-stage development of its cancer-drug azenosertib.

Studies going back decades have shown a potential link between artificial food dyes and attention deficit hyperactivity disorder symptoms in kids.

Over 35 years after the first study linking the artificial food dye Red 3 to thyroid cancer in rats was published, the U.S. is beginning to phase it out of foods and drugs.

On January 15, 2025, the Food and Drug Administration (FDA) amended its color additive regulations by revoking its authorization for use in food

Robert F. Kennedy Jr. may soon be America's top pharmaceutical regulator. That is cause for concern in Seattle’s biotech sector, but industry leaders believe science may carry the day.

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: NCT04494425 ).

The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer with disease progression after endocrine therapy.